Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway

ContextAsthma is a common respiratory system disease. Louki Zupa decoction (LKZP), a traditional Chinese medicine, presents a promising efficacy against lung diseases.ObjectiveTo investigate the pathogenic mechanism of asthma and reveal the intervention mechanism of LKZP.Materials and methodsForty-eight female Balb/c mice were randomly divided into 6 groups: normal control group (NC), ovalbumin (OVA)/saline asthma model group, OVA/LL group, OVA/LM group, OVA/LH group and OVA/DEX group (n = 8 per group). The asthmatic mice were modelled through intraperitoneal injecting and neutralizing OVA. LKZP decoction was administrated by gavage at the challenge stage for seven consecutive days (2.1, 4.2 and 8.4 g/kg/day). We investigated the change in lung function, airway inflammation, mucus secretion and TH-1/TH-2-related cytokines. We further verify the activated status of the IL-33/ST2/NF-κB/GSK3β/mTOR signalling pathway.ResultsLKZP was proved to improve asthmatic symptoms, as evidenced by the down-regulated airway resistance by 36%, 58% and 53% (p < 0.01, p < 0.001 vs. OVA/saline group), up-regulated lung compliance by 102%, 114% and 111%, decreased airway inflammation and mucus secretion by 33%, 40% and 33% (p < 0.001 vs. OVA/saline group). Moreover, the content of cytokines in BALF related to airway allergy (such as IgE) and T helper 1/T helper 2 cells (like IL-2, IL-4, IL-5, IL-13, TNF-α and IFN-γ), were also markedly reduced by 13–65% on LKZP intervention groups compared with model group. Mechanistic research revealed that the IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway was activated in the OVA/saline group and LKZP significantly down-regulated this pathway.Discussion and conclusionLKZP improves lung function, airway inflammation, mucus secretion and correct immune imbalance by intervening with the IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway, presenting a promising therapeutic choice for asthma.     

针刺治疗慢性功能性便秘的临床观察

目的:观察针刺对功能性便秘的疗效,并探讨其作用机理.方法:选择功能性便秘患者40例,随机分成治疗组及对照组各20例,治疗组每日针刺1次,每次15～20min,5天为1疗程,隔两天继续第2个疗程,共3个疗程;对照组以西沙比利片10mg,每天3次,餐前半小时服用,连续4周.观察两组治疗前后大便次数,大便性状,排便困难程度以及结肠通过时间的变化.结果:两组治疗后各观察指标较治疗前有明显改善(P＜0.01),两组治疗后比较差异无显著性(P＞0.05).结论:针刺能够改善功能性便秘的结肠动力,对功能性便秘疗效确切.     

保守治疗膝骨性关节炎64例

[目的]观察保守疗法治疗膝骨性关节炎的临床疗效。[方法]64例全部采用新止骨增生丸结合透明质酸钠治疗。[结果]治愈38例,好转20例,未愈6例,总有效率约为90%。[结论]保守疗法治疗膝骨性关节炎可以起到很好的治疗作用。     

Effect of EGb761 on light-damaged retinal pigment epithelial cells

AIM:To investigate the protective mechanism of Gingko Biloba extract (EGb761) on the ability of retinal pigment epithelial (RPE) cells to resist light-induced damage in a comparative proteomics study.METHODS:Human RPE cells (ARPE-19) were randomly distributed to one of three groups:normal control (NC group) and light-damaged model without or with EGb761 group (M and ME groups, respectively). The light-damaged model was formed by exposing to white light (2 200±300)lx for 6h. The RPE cells in ME group were conducted with EGb 761 (100μg/mL) before light exposure. The soluble cellular proteins extracting from each groups were separated by two-dimensional electrophoresis and stained by silver staining. Different proteins in the profiles of the gels were analyzed by Image Master Software. Two-fold expressing protein spots were identified by Matrix-assisted laser desorption/ionization tandem time-of-flight (MALDI-TOF/TOF) mass spectrometry.RESULTS: NC, M and ME groups displayed 1 892±71, 2 145±23 and 2 216±85 protein spots, respectively. We identified 33 proteins with different expression levels between the NC and M groups, 25 proteins between the M and ME groups, and 11 proteins between the NC and ME groups. MALDI-TOF/TOF mass spectrometry successfully identified 16 proteins, including metabolic enzymes, cytoskeletal proteins, anti-oxidation proteins, and others.CONCLUSION:Differences in some important proteins, such as cathepsin B, heat shock protein, and cytochrome creductase, indicated that multiple pathways may be induced in light-damaged RPE cells and the protective effect of EGb761.     

大鼠离体肝脏灌流系统的建立

目的：建立大鼠离体肝动脉／门静脉灌流系统的实验方法。方法：雌性Wistar大鼠麻醉状态下,肝动脉、门静脉和肝静脉插管;经肝动脉冲净残留血液,灌流状态下游离肝脏;定量蠕动泵调节肝动脉或门静脉的Krebs—Henseleit平衡液（或加等渗葡聚糖）的灌流流速,泰盟BL-420S生物机能实验系统监测肝动脉或门静脉的压力变化,采用Prism-4非线型可变斜率回归获得“有或无胶体渗透压”KH液灌流的流速-压力曲线及方程式,计算半效流速及其95％的可信限。结果：无胶体渗透压灌流状态下的肝脏系数无差别,肝动脉的半效流速为2217（95％CI1209～4068）μl·min^－1,对数流速-压力直线方程为Y=142．4x＋706．9;门静脉半效流速为3791（95％CI3549～4049）μl·min^－1,对数流速-压力直线方程为Y：479．6X＋5034。等效胶体渗透压灌流状态下的肝脏系数无差别,肝动脉半效流速为3754（95％CI3175～4440）μl·min^－1,对数流速-压力直线方程为Y=133．5X-719．0;门静脉半效流速为6018（95％CI5565—6508）μl·min^－1,对数流速-压力直线回归方程为Y：538．3X4-4704。半效流速接近正常大鼠生理平均值,各半效流速95％可信限涵盖大鼠正常生理状态的变化范围。有或无胶体渗透压灌流状态之间总体无差别。结论：在恒流测压模式下,等渗灌流大鼠离体肝动脉和门静脉灌流系统的视窗时程长、机能变化稳定、操作流程简便,为认识肝动脉和门静脉离体舒缩机制奠定了基础。     

良性前列腺增生症的药物治疗与评价

目的:伴随老龄社会深化和人数增加,属于老年医学范畴的一组泌尿系统疾病(良性前列腺增生症、前列腺癌、前列腺炎、勃起功能障碍、早泄和膀胱过度活动症)的治疗正日益受到关注,用药情况呈明显上升趋势,本文对抗前列腺增生药的临床应用进行分析评价。方法:采用国内外文献分析方法。结果与结论:抗良性前列腺增生症药的合理和安全应用尤为重要。     

急性缺血性卒中静脉溶栓治疗后大脑中动脉再通患者的临床预后研究

目的：探讨急性缺血性卒中接受重组组织型纤溶酶原激活剂（ Recombinant Tissue Plasminogen Activa-tor,rt-PA）静脉溶栓治疗后大脑中动脉再通患者的临床预后情况。方法回顾性分析2013年9月至2014年9月,于天津市环湖医院神经内科接受静脉溶栓治疗的急性缺血性卒中患者资料552例。入选患者按照0．9 mg／kg剂量标准,给予rt-PA静脉溶栓治疗。所有患者于溶栓前及溶栓后24 h进行头部MRA检查,采用TICI血管再通分级标准判断大脑中动脉的再通情况。其中根据溶栓后24 h MRA检查结果分为血管再通组（188例）,血管未通组（364例）。溶栓前及溶栓后24 h的神经功能缺损评分及疗效判定,采用美国国立卫生研究院卒中量表（ National Institute of Health Stroke Scale,NIHSS）。神经功能的预后评价,采用改良Rankin评分（ modified Rankin Scale,mRS）。对2组患者溶栓后颅内出血（ intracranial hemorrhage,ICH）、症状性颅内出血（ symptomatic intracranial hemorrhage,SICH）的发生率、死亡率、神经功能缺损恢复及预后情况进行统计对比分析。结果血管再通组患者的恢复良好率和预后良好率均高于血管未通组,差异有统计学意义（ P ＜0．05）。血管再通组患者未出现症状性颅内出血,有6例患者出现了非症状性颅内出血。血管再通组及血管未通组的颅内出血发生率、其他部位出血率和住院期间死亡率差异均无统计学意义（P＞0．05）。结论研究结果表明,急性缺血性卒中患者在接受静脉溶栓治疗后,大脑中动脉再通的患者较未通患者神经功能缺损症状改善明显。静脉溶栓后,血管再通的患者临床预后获益更大。     

向日葵胰蛋白酶抑制剂SFTI的合成及酶抑制动力学研究

目的 考察合成的向日葵胰蛋白酶抑制剂的抑制效果,计算其抑制常数Ki.方法 采用Fmoc固相化学合成方法,反相柱纯化后用CytofluorTM微孔板发光检测仪测定向日葵胰蛋白酶抑制剂的抑制常数.结果与结论 向日葵胰蛋白酶抑制剂的Ki值为2.2nM±0.5(n=8),抑制效果良好.     

肺炎清止咳祛痰平喘作用的实验研究

目的：通过肺炎清的动物实验研究,探讨其止咳祛痰平喘作用.方法：参考相关文献制备小鼠模型,观察不同剂量肺炎清(大剂量组：每20 g小鼠用0.500 mL；中剂量组：每20 g小鼠用0.250 mL；小剂量组：每20 g小鼠用0.125 mL)对小鼠止咳、祛痰、平喘等作用.结果：止咳作用表明：肺炎清大、中、小剂量组均能够明显延长咳嗽潜伏期,减少咳嗽次数,与对照组比较差异有极显著性(P＜0.01)；祛痰作用表明：肺炎清大剂量组有明显祛痰作用,与对照组比较差异有显著性(P＜0.05).平喘作用表明：肺炎清大、中、小剂量组均能够明显抑制哮喘反应,潜伏期明显延长,与对照组比较差异有极显著性(P＜0.01).结论：肺炎清具有明显的止咳、祛痰、平喘等作用.     

经导管主动脉瓣置换术后抗栓治疗策略

目前,经导管主动脉瓣置换术(TAVR)后抗栓治疗方案尚不统一,因此为TAVR术后患者选择最佳的抗栓策略,实现个体化的抗栓治疗就成为了当前TAVR术后患者管理的重要内容。术后选择双联抗血小板、单药抗血小板和(或)抗凝治疗是目前TAVR术后抗栓治疗的主要策略。一方面目前TAVR适应证人群常合并肝肾功能不全、冠状动脉粥样硬化性心脏病、糖尿病、肿瘤、心房颤动等出血或血栓形成的高危因素,另一方面以术后影像学表现为主导的亚临床血栓是否需要更安全积极的抗栓方案尚无明确临床研究证据。该文探讨并梳理了TAVR术后抗栓治疗的进展。